Planning meals ahead ensures you consistently fuel your body with foods that trigger GLP-1 release, aiding in weight management and overall health
At 72 weeks, all doses (6 mg, 12 mg, 36 mg) met the primary endpoint of superior body weight reduction versus placebo and achieved key secondary goals including 10%, 15%, and 20% weight loss and reduced waist circumference
Pancreatitis: Case studies and a few of the clinical trials on GLP-1 RAs for diabetes have raised the possibility of pancreatitis being triggered by these drugs due to the potential growth in cells in the pancreas
Individual experiences vary
BMI Between 30 and 35 Requires associated conditions such as uncontrolled hypertension or advanced stage chronic kidney disease
GIP receptor agonism attenuates GLP-1 receptor agonist induced nausea and emesis in preclinical models